Pharma Clinical Trial Services: World Market 2013-2023

January 2013 | 189 pages | ID: PDCE45635B9EN
Visiongain

Abstracts

Discover new trends, opportunities and prospects for contract clinical trials

What's the outlook for clinical research providers? Visiongain's updated report gives you forecasted revenues to 2023. It explains trends, opportunities and commercial prospects.

Our study lets you assess sales data at overall world market, submarket and national level. There you find the most promising and lucrative areas in clinical trial outsourcing, helping your research and analyses.

Forecasts and other analyses to help you stay ahead in knowledge

In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends (R&D). You receive 74 tables, 61 charts and two survey interviews.

There's rising demand for that pharma research. The outsourced clinical trials market will increase its revenues from 2013 to 2023, achieving strong growth. Clinical research organisations (CROs) and their clients will benefit.

The following sections show what you find in our new report.

Discover prospects for the world market and submarkets

Along with revenue prediction for the overall world market, you see forecasts to 2023 for eight submarkets:

• Early phase clinical trial services
• Late phase services.

We also show forecasts for contract services by therapeutic area:

• Cancers
• Central nervous system (CNS) diseases
• Cardiovascular diseases
• Infections
• Metabolic disorders
• Other therapy areas (grouped prediction).

You gain advantages by understanding trends, opportunities and challenges. Our investigation shows what will stimulate and restrain business for CROs.

Our work also breaks the main world forecast into geographical markets.

What prospects for leading regions and countries?

Developments worldwide will influence the market from 2013, especially improving clinical research in developing countries. There exist many opportunities for pharmaceutical companies and contract research providers. See outlooks for clinical testing.

You get individual forecasts to 2023 for 12 national markets and two regional groups, finding overall revenues:

• US
• Japan
• Western Europe
• Central and Eastern Europe (CEE)
• Germany, France, UK, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC nations) and South Korea.

Discover progress and outlooks. You assess the industry's future - hear about developments and find their significance. Our work explains, exploring many issues.

What affects clinical trial services from 2013?

Our report discusses issues and events affecting that industry and market from 2013:

• Future of outsourced phase I, II and III trials and post-marketing studies
• Demand from pharmaceutical and biopharma companies
• Regulatory policy
• Challenges in developed and developing countries
• Adaptive trial designs and focus on late-stage R&D pipeline candidates
• Patient recruitment and retention.

Also, we discuss these aspects of the field:

• Social media as tools for engaging patients
• Technological progress for more-efficient trials
• Sharing of risk between the pharma industry and CROs
• CRO consolidation, specialisation and globalisation
• Studies on orphan diseases
• Biomarkers in drug development.

See what the future holds. You investigate technological, economic and political matters, finding emphasis on companies, competition and business outlooks.

Leading companies and 2015 market value

We predict that the overall world market for clinical trial services will reach $30.6bn in 2015, and expand further to 2023. That outsourcing segment holds great potential for investment, development and revenue growth from 2013. You see how it will progress.

We review 15 leading companies, including these:

• Quintiles
• Covance
• PPD
• Parexel International
• ICON
• INC Research
• inVentiv Health.

From 2013 to 2023, many opportunities will arise. Our work shows you the technological and commercial possibilities.

Eight ways Pharma Clinical Trial Services: World Market 2013-2023 helps

To sum up, our investigation gives you the following knowledge:

• Revenues to 2023 for the overall world market and 8 submarkets - you discover the industry's prospects
• Market forecasting to 2023 for US, Japan, Germany, France, UK, Spain, Italy, South Korea, Brazil, Russia, India and China - you see national sales predictions
• Investigation of clinical trial services - out-contracting and off-shoring - you assess outlooks for pharma CROs and their clients
• Profiles of 15 leading companies - you hear about activities, recent results, strategies and outlooks for top service providers
• Opinions on the sector - you read our interviews with authorities in the industry
• Competition and opportunities influencing sales - you see what affects the future
• Discussions of what stimulates and restrains the industry and market - you explore business trends, drivers and restraints
• Prospects for established firms and those seeking to enter the sector - you assess needs, practices and outlooks for success.

You gain information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where technological and financial prospects are good.

With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, saving time and getting you recognition for insight.

Ordering now lets you discover commercial predictions to 2023

Visiongain's investigation is for everyone needing analysis of the clinical trials industry and market. You find data, trends and predictions. Please order our report now.

Contents

1. EXECUTIVE SUMMARY

1.1 Pharma CliniCal Trial ServiCes: World Market Review
1.2 Report Contents
1.3 ResearCh and Analysis Methods

2. AN INTRODUCTION TO CLINICAL TRIAL OUTSOURCING

2.1 A Brief History of CliniCal Trials
2.2 CliniCal Trial Design and ExeCution
  2.2.1 Phases of CliniCal Trials
    2.2.1.1 Phase I Trials: First-in-Human Studies
    2.2.1.2 Phase II Trials: Proof-of-ConCept
    2.2.1.3 Phase III Trials: Preparing for Approval AppliCations
    2.2.1.4 Post-Marketing Studies
  2.2.2 Key Elements of CliniCal Trials
  2.2.3 Common Trial Designs
    2.2.3.1 Improving CliniCal Trial Models Through Adaptive Trial Designs
2.3 CliniCal Trial OutsourCing
  2.3.1 Challenges Exist in ConduCting CliniCal Trials
  2.3.2 Benefits of OutsourCing

3. THE WORLD PHARMA CLINICAL TRIAL SERVICES MARKET 2013-2023

3.1 The Pharma CliniCal Trial ServiCes Market 2011-2012
  3.1.1 Rapid Growth in the CliniCal Trial OutsourCing Market 2008-2011
  3.1.2 CRO Revenue by Trial Phase 2011
  3.1.3 Big Pharma Companies Are the Leading Clients for CROs
3.2 The Pharma CliniCal Trial ServiCes Market 2013-2023
  3.2.1 What Will Drive Growth in CliniCal Trial OutsourCing 2013-2023?
  3.2.2 The Pharma CliniCal Trial ServiCes Market: Overall Revenue ForeCast 2013-2023
  3.2.3 WhiCh Market SeCtor Will ACCount for Most Revenue 2013-2023?
3.3 Early Phase CliniCal Trial ServiCes 2013-2023
  3.3.1 Rising Demand for Early Phase ServiCes Throughout the DeCade
  3.3.2 BioteCh OutsourCing to Drive Early Phase Growth
3.4 Late Phase CliniCal Trial ServiCes 2013-2023
  3.4.1 Late Phase CliniCal Trial ServiCes: The Largest Market SeCtor 2013-2023
  3.4.2 FoCus on Last-Stage Pipeline Candidates Early in the DeCade

4. PHARMA CLINICAL TRIAL SERVICES: LEADING DEVELOPED MARKETS 2013-2023

4.1 Leading National Markets for Pharma CliniCal Trial ServiCes 2011
4.2 Pharma CliniCal Trial ServiCes: Leading National Market ForeCasts 2013-2023
4.3 North AmeriCa as a Destination for CliniCal Trials
  4.3.1 The US: The Largest National Market for CliniCal Trial ServiCes 2013-2023
    4.3.1.1 Regulatory Developments to Improve CliniCal Trials in the US
  4.3.2 The US: CliniCal Trial ServiCe Revenue ForeCast 2013-2023
4.4 The Outlook for CliniCal Trial ServiCes in Western Europe 2013-2023
  4.4.1 Rewriting the Rules for CliniCal Trials in the EU
  4.4.2 Western Europe: Overall Market and Leading National Market ForeCasts 2013-2023
  4.4.3 Germany Is the Largest Market for CliniCal Trial ServiCes in Western Europe
  4.4.4 FranCe: Market ForeCast 2013-2023
  4.4.5 The UK
    4.4.5.1 OverComing Challenges in UK CliniCal Trials
    4.4.5.2 UK CliniCal Trial ServiCes Market ForeCast 2013-2023
  4.4.6 Italy
  4.4.7 Spain: Market ForeCast 2013-2023
4.5 Japan Is Being Challenged by Neighbouring Emerging Markets
  4.5.1 Regulatory PoliCies Driving and Restraining Growth in Japan
  4.5.2 Growth for CliniCal Trial ServiCes in Japan 2013-2023

5. PHARMA CLINICAL TRIAL SERVICES: LEADING EMERGING MARKETS 2013-2023

5.1 Leading Emerging Markets for CliniCal Trial ServiCes 2011
  5.1.1 Benefits of ConduCting CliniCal Trials in Emerging National Markets
  5.1.2 Challenges of ConduCting CliniCal Trials in Emerging Markets
5.2 Strong Growth ForeCast for Emerging CliniCal Trial ServiCe Markets 2013-2023
5.3 CliniCal Trials in Asia PaCifiC: An Emerging Market PerspeCtive
  5.3.1 India as a Hub for CliniCal Trials
    5.3.1.1 InCreasingly StriCt Regulatory ProCedures in India
    5.3.1.2 Indian CliniCal Trial ServiCes Market ForeCast 2013-2023
  5.3.2 China Will be the Largest Emerging Market for CliniCal Trials ServiCes in 2023
    5.3.2.1 China Offers Many Advantages in CliniCal Trials
    5.3.2.2 New Guidelines for Phase I Trials
  5.3.3 South Korea
    5.3.3.1 Improving the Appeal of South Korea
    5.3.3.2 Promoting LoCal Drug Development in South Korea
    5.3.3.3 Growth in the South Korean CliniCal Trials ServiCes Market 2013-2023
5.4 CliniCal Trial OutsourCing in Central and Eastern Europe (CEE)
  5.4.1 Russia
    5.4.1.1 Changing CliniCal Trial Demands 2010-2012
    5.4.1.2 Russian CliniCal Trial ServiCes Market ForeCast 2013-2023
  5.4.2 CEE: CliniCal Trial ServiCes Market ForeCast 2013-2023
5.5 Latin AmeriCa: Proximity to the US as a Growth Driver
  5.5.1 Brazil: The Largest Market for CliniCal Trials in Latin AmeriCa 2013-2023
    5.5.1.1 Brazilian CliniCal Trial ServiCes Market ForeCast 2013-2023

6. LEADING DISEASE MARKET SECTORS FOR CLINICAL TRIAL SERVICES 2013-2023

6.1 The Pharma CliniCal Trial ServiCes Market by TherapeutiC Area 2011-2012
6.2 The Pharma CliniCal Trial ServiCes Market: Revenue ForeCast by TherapeutiC Area 2013-2023
6.3 Imaging for CNS and CardiovasCular CliniCal Trials
6.4 CanCer CliniCal Trials: Key Trends and Submarket ForeCast 2013-2023
  6.4.1 Biomarkers and Companion DiagnostiC Development
  6.4.2 Optimising Patient ReCruitment and Retention
  6.4.3 Many FaCtors CompliCate CanCer CliniCal Trials
  6.4.4 The Largest Submarket for CliniCal Trial ServiCes 2013-2023?
6.5 CNS CliniCal Trials: Key Trends and Submarket ForeCast 2013-2023
  6.5.1 ConCerns with PlaCebo Response Rates in CNS CliniCal Trials
    6.5.1.1 Cogtest: Data Capture and Cognitive Assessment
  6.5.2 EffeCtive Use of Adaptive Trial Designs
  6.5.3 CNS CliniCal Trials: Submarket ForeCast 2013-2023
6.6 CardiovasCular Disease CliniCal Trials: Key Trends and Submarket ForeCast 2013-2023
  6.6.1 Strong Growth in the CardiovasCular Disease CliniCal Trial ServiCes Submarket 2013-2023
6.7 InfeCtious Disease CliniCal Trials: Key Trends and Submarket ForeCast 2013-2023
  6.7.1 Challenges in the Use of Non-Inferiority Trials
  6.7.2 Considerations for AntibaCterial Drug CliniCal Trials
  6.7.3 VaCCine CliniCal Trials and Emerging Markets
  6.7.4 InfeCtious Disease CliniCal Trial ServiCes Submarket ForeCast 2013-2023
6.8 MetaboliC Disease CliniCal Trials: Key Trends and Submarket ForeCast 2013-2023
  6.8.1 Assessing CardiovasCular Risks in Diabetes
  6.8.2 MetaboliC Disease CliniCal Trial ServiCes Submarket ForeCast 2013-2023
6.9 TherapeutiC Expertise Provides an Opportunity for SpeCialisation
  6.9.1 CROs Offering Imaging ServiCes

7. PHARMA CLINICAL TRIAL SERVICES MARKET: INDUSTRY TRENDS 2013-2023

7.1 Pharma CliniCal Trial ServiCes Market: Strengths and Weaknesses 2012
7.2 Pharma CliniCal Trial ServiCes Market: Opportunities and Threats 2013-2023
  7.2.1 CRO Expertise in Biosimilars as an Opportunity
7.3 Pharma CliniCal Trial ServiCes Market: STEP Analysis 2013-2023
7.4 SoCial FaCtors AffeCting CliniCal Trials 2013-2023
  7.4.1 Drug Developers Must Deal with EthiCal Considerations to CliniCal Trials
  7.4.2 Patient ReCruitment: The Leading Cause of Trial Delays
  7.4.3 Investing to Maintain Patient Enrolment
    7.4.3.1 SoCial Media as a Tool for Engaging Patients in Trials
7.5 Improving TeChnology for More-EffiCient Trials
  7.5.1 eCliniCal Trial Tools
    7.5.1.1 EleCtroniC Health ReCords for Faster Patient ReCruitment
  7.5.2 Cloud Computing as a Tool for MultiCentre Trials
  7.5.3 EleCtroniC Data Capture
7.6 EConomiC Considerations for CliniCal Trial OutsourCing
  7.6.1 Pharma is Adjusting its R&D Strategies
  7.6.2 CROs are AttraCtive for Private Investors
7.7 PolitiCal and Regulatory Developments AffeCting CliniCal Trials
  7.7.1 Drug Safety and CliniCal Trials Post-Approval
  7.7.2 Cutting Red Tape and Other Regulatory Developments
7.8 Future Growth Strategies for CROs
  7.8.1 StrategiC Partnering for Long Term Revenue Growth
    7.8.1.1 Sharing Risk Between Pharma and CROs
  7.8.2 What Strategies Are Used for SeleCting a CRO?
    7.8.2.1 Small PharmaCeutiCal Companies and CROs
  7.8.3 CRO Consolidation is DeCreasing the Number of Mid Sized Market Players
  7.8.4 CROs Can SpeCialise to Grow
    7.8.4.1 Orphan Diseases Are an Opportunity for SpeCialisation
7.9 The Future of CliniCal Trials and CROs
  7.9.1 New Trial Designs
    7.9.1.1 Optimising CliniCal Trials for EffiCient Drug Development
  7.9.2 CliniCal Trial Globalisation
    7.9.2.1 ConsequenCes of InCreased OutsourCing to Emerging Markets
  7.9.3 CliniCal Trials Have BeCome InCreasingly Complex
7.10 Biomarkers Are Useful Tools for ACCelerating Drug Development

8. LEADING CROS IN THE CLINICAL TRIALS SERVICES INDUSTRY IN 2013

8.1 The Pharma CliniCal Trial ServiCes Market by Company 2011-2012
8.2 Quintiles: The Largest Player in the Pharma CliniCal Trial ServiCes Market
  8.2.1 EmbraCing TeChnology for New ServiCe Offerings
  8.2.2 Expanding in Developed and Emerging Markets
  8.2.3 Will Quintiles Remain the Market Leader to 2023?
8.3 CovanCe Is a Market Leader in Early Phase ServiCes
  8.3.1 CovanCe Reorganises its Early Phase Sites
  8.3.2 Strong Late Phase Revenue Growth 2007-2011
  8.3.3 How Will CovanCe Extend its ServiCes Beyond 2012?
8.4 PPD
  8.4.1 PPD: Another Global CRO to be Taken Private
  8.4.2 Investing in TeChnology for Growth
  8.4.3 PPD: Outlook 2013-2023
8.5 Parexel International
  8.5.1 Parexel is Targeting Growth in Asia
  8.5.2 Strong Growth for CliniCal Trial ServiCes 2010-2012
  8.5.3 New Areas of SpeCialisation for Parexel
8.6 ICON
  8.6.1 Multiple ACquisitions Have InCreased ICON's ServiCe Range
    8.6.1.1 Expanding Operations in China
  8.6.2 ICON: ReCent FinanCial PerformanCe and Outlook 2013-2023
8.7 INC ResearCh
  8.7.1 From Mid-Sized to Large CRO: INC ACquires Kendle
  8.7.2 INC Adds New TeChnologiCal Capabilities
8.8 inVentiv Health
  8.8.1 Three ACquisitions Move inVentiv Closer to the Big Players
  8.8.2 CliniCal Trial ServiCe Revenue Growth 2011 and Beyond
8.9 PRA International
  8.9.1 New Site Openings in Emerging Markets 2011-2012
  8.9.2 Future DireCtions for PRA International
8.10 CMIC: Japan's Largest CRO
  8.10.1 InCreasing Asian Regional ReaCh
  8.10.2 CMIC ReCent and Future PerformanCe Analysis: An Asian SpeCialist
8.11 Chiltern International
  8.11.1 Expanding into New Emerging Markets with OffiCes in Israel and Taiwan
  8.11.2 Chiltern International: Opportunities for Growth 2013-2023
8.12 There Are Many Other CROs in the Market in 2012
  8.12.1 Charles River Laboratories Is an Expert in Pre-CliniCal ServiCes
  8.12.2 ClinipaCe Worldwide Is a Digital CRO
    8.12.2.1 Rapidly Expanding Through ACquisitions
    8.12.2.2 ClinipaCe Offers Many TeChnology Solutions
  8.12.3 ReSearCh PharmaCeutiCal ServiCes (RPS)
  8.12.4 Theorem CliniCal ResearCh
    8.12.4.1 An Established PresenCe in China
  8.12.5 WuXi PharmaTeCh
    8.12.5.1 WuXi is New to the CliniCal Trial ServiCes Market
8.13 Leading Company Analysis
  8.13.1 Emerging Market Entry and Expansion
  8.13.2 How Are Global CROs Using TeChnology?
  8.13.3 How Are Leading Players Seeking to Differentiate Themselves?
  8.13.4 Medium-Sized Players Growing Larger Through Multiple ACquisitions
  8.13.5 Large CROs and StrategiC Partnerships with Big Pharma

9. RESEARCH INTERVIEWS

9.1 Jodi Andrews, CEO, ProTrials ResearCh
  9.1.1 ProTrials ResearCh
  9.1.2 The ImportanCe of the European Market
  9.1.3 Expansion to Meet Demand
  9.1.4 The Role of Small and Medium-Sized CROs in the Market
  9.1.5 TeChnologiCal Developments to Benefit CliniCal Trials 2013-2023
  9.1.6 Trends AffeCting CliniCal Trial OutsourCing 2013-2023
9.2 Dr Vladimir Bogin, President and CEO, Cromos Pharma
  9.2.1 Cromos Pharma
  9.2.2 The Advantages of Regional SpeCialisation
  9.2.3 Considerations for ConduCting Trials in the CEE Region
  9.2.4 Future Growth Opportunities in the CEE Region
  9.2.5 Challenges for ConduCting Trials in the CEE Region

10. CONCLUSIONS FROM OUR STUDY

10.1 The State of the CliniCal Trial ServiCes Market
  10.1.1 A Market Dominated by the Developed Countries
10.2 Strong Growth for the Overall Market 2013-2023
10.3 WhiCh CROs Can Take Best Advantage of Market Growth in the Next 10 Years?
  10.3.1 The Role of TeChnology in the Future of CliniCal Trial ServiCes
  10.3.2 How Can CROs SpeCialise to Remain Competitive?

List Of Tables

LIST OF TABLES

Table 1.1 CurrenCy ExChange Rates, 2011
Table 2.1 Founding Members of the ICH
Table 2.2 Types of Adaptive Trial Design
Table 3.1 Breakdown of Pharma CliniCal Spending by Phase
Table 3.2 Pharma CliniCal Trial ServiCes Market, 2008-2011
Table 3.3 Pharma CliniCal Trial ServiCes Market by SeCtor, 2011
Table 3.4 CRO CliniCal Trial ServiCes Revenue by Customer Type, 2011
Table 3.5 Pharma CliniCal Trial ServiCes Market: Overall Market and Revenue ForeCasts by SeCtor, 2011-2023
Table 3.6 CliniCal Trial ServiCes Submarket Shares, 2011-2023
Table 3.7 Early Phase CliniCal Trial ServiCes Submarket ForeCast, 2011-2023
Table 3.8 Late Phase CliniCal Trial ServiCes Submarket ForeCast, 2011-2023
Table 4.1 World Pharma CliniCal Trial ServiCes Market by Region, 2011
Table 4.2 Pharma CliniCal Trial ServiCes Market: Revenue ForeCasts by Country, 2011-2023
Table 4.3 Pharma CliniCal Trial ServiCes: Market Shares by Country, 2011-2023
Table 4.4 US CliniCal Trial ServiCes Market ForeCast, 2011-2023
Table 4.5 Western European CliniCal Trial ServiCes Market by Country, 2011
Table 4.6 Western European CliniCal Trial ServiCes Market: Revenue ForeCasts by Country, 2011-2023
Table 4.7 German CliniCal Trial ServiCes Market ForeCast, 2011-2023
Table 4.8 FrenCh CliniCal Trial ServiCes Market ForeCast, 2011-2023
Table 4.9 UK CliniCal Trial ServiCes Market ForeCast, 2011-2023
Table 4.10 Italian CliniCal Trial ServiCes Market ForeCast, 2011-2023
Table 4.11 Spanish CliniCal Trial ServiCes Market ForeCast, 2011-2023
Table 4.12 Japanese CliniCal Trial ServiCes Market ForeCast, 2011-2023
Table 5.1 Leading Emerging Markets for Pharma CliniCal Trial ServiCes, 2011
Table 5.2 Population StatistiCs in BRIC Nations, 2012
Table 5.3 Relative CompetenCe in English in Emerging Markets, 2012
Table 5.4 Pharma CliniCal Trial ServiCes Market: Revenue ForeCasts in Emerging Markets, 2011-2023
Table 5.5 Indian CliniCal Trial ServiCes Market ForeCast, 2011-2023
Table 5.6 Chinese CliniCal Trial ServiCes Market ForeCast, 2011-2023
Table 5.7 South Korean CliniCal Trial ServiCes Market ForeCast, 2011-2023
Table 5.8 Russian CliniCal Trial ServiCes Market ForeCast, 2011-2023
Table 5.9 CEE CliniCal Trial ServiCes Market ForeCast, 2011-2023
Table 5.10 Brazilian CliniCal Trial ServiCes Market ForeCast, 2011-2023
Table 6.1 Global CliniCal Trials by TherapeutiC Area, 2012
Table 6.2 Leading TherapeutiC Areas for CliniCal Trial ServiCes, 2011
Table 6.3 CliniCal Pipelines for Leading TherapeutiC Areas, 2010-2012
Table 6.4 Pharma CliniCal Trial ServiCes Market: Revenue ForeCasts for Leading TherapeutiC Areas, 2011-2023
Table 6.5 Leading CROs SpeCialising in Biomarker ServiCes, 2012
Table 6.6 CanCer CliniCal Trial ServiCes Submarket: Drivers and Restraints, 2011-2023
Table 6.7 CanCer CliniCal Trial ServiCes Submarket ForeCast, 2011-2023
Table 6.8 Late-Stage Pipeline Failures in Alzheimer's Disease, 2009-2012
Table 6.9 CNS Disease CliniCal Trial ServiCes Submarket: Drivers and Restraints, 2011-2023
Table 6.10 CNS Disease CliniCal Trial ServiCes Submarket ForeCast, 2011-2023
Table 6.11 CardiovasCular Disease CliniCal Trial ServiCes Submarket ForeCast, 2011-2023
Table 6.12 CardiovasCular Disease CliniCal Trial ServiCes Submarket: Drivers and Restraints, 2011-2023
Table 6.13 ChroniC Hepatitis B & C: Global PrevalenCe by Region, 2012
Table 6.14 InfeCtious Disease CliniCal Trial ServiCes Submarket ForeCast, 2011-2023
Table 6.15 InfeCtious Disease CliniCal Trial ServiCes Submarket: Drivers and Restraints, 2011-2023
Table 6.16 MetaboliC Disease CliniCal Trial ServiCes Submarket ForeCast, 2011-2023
Table 6.17 MetaboliC Disease CliniCal Trial ServiCes Submarket: Drivers and Restraints, 2011-2023
Table 6.18 SeleCted Imaging SpeCialist CROs, 2012
Table 7.1 Pharma CliniCal Trial ServiCes Market: Strengths and Weaknesses, 2012
Table 7.2 Pharma CliniCal Trial ServiCes Market: Opportunities and Threats, 2013-2023
Table 7.3 Biosimilar GuidanCe Drafted Using Elements of EU Guidelines, 2008-2012
Table 7.4 Pharma CliniCal Trial ServiCes Market: STEP Analysis, 2013-2023
Table 7.5 SeleCted Online Communities to Aid Patient ReCruitment and Trial Involvement, 2012
Table 7.6 SeleCted CROs Investing in TeChnology, 2011-2012
Table 7.7 SeleCted SourCes of Biomarkers and Relevant ResearCh TeChnology, 2012
Table 7.8 Growth in the Biomarker ServiCes Market, 2011, 2016 & 2022
Table 8.1 World CRO Market by Company, 2011
Table 8.2 CovanCe: Revenue by SeCtor, 2007-2011
Table 8.3 CovanCe: Revenue by SeCtor, Q1-Q3 2011-2012
Table 8.4 PPD: Revenue by SeCtor, Q1-Q2 2010-2011
Table 8.5 Parexel International: Revenue by SeCtor, 2010-2012
Table 8.6 Parexel International: Revenue by Region, 2012
Table 8.7 ICON: Revenue by SeCtor, 2010-2011
Table 8.8 ICON: Revenue by Region, 2010-2011
Table 8.9 Kendle: Revenue by SeCtor, 2009-2010
Table 8.10 inVentiv Health: Revenue by SeCtor, Q2 2010 & Q2 2011
Table 8.11 CMIC: CRO Revenue, 2008-2012
Table 8.12 Chiltern International: TherapeutiC ExperienCe
Table 8.13 Chiltern International: Revenue, 2008-2010
Table 8.14 SeleCted StrategiC Partnerships Signed, 2011-2012
Table 10.1 Pharma CliniCal Trial ServiCes Market by SeCtor, 2011, 2017 & 2023

About

Vaccine Clinical Trials and Emerging Markets

Vaccines, for infectious diseases and other indications, provide unique challenge in terms of clinical trials. In order to enrol enough patients that will have the disease, trials for prophylactic vaccines must recruit a large number of participants in region with the highest prevalence. As these tend to be emerging markets, these are the best countries in which to conduct trials. However, the infrastructure required for large trials may not be in place in these countries, particularly in African nations. For vaccines targeting seasonal infections, timing can also be an issue: the patients need to be enrolled and vaccinated prior to the beginning of the infectious season in order to ensure that vaccine has a chance of working. Therefore fast enrolment is required. Regulatory bodies have suggested that adaptive trial designs may be suitable for testing vaccines. In August 2012, the FDA’s Center for Biologics Evaluation and Research (CBER)announced that it would be investing up to $12m in assessing adaptive trials for vaccine development.

Infectious Disease Clinical Trial Services Submarket Forecast 2013-2023

The infectious disease clinical trial services submarket will grow with a CAGR of 9.6% from 2011 to 2023. In this time the submarket will grow from $2.34bn to $7.01bn. Growth will be fastest in the second half of the forecast period, following the trend of the clinical trial services market as a whole. Growth will be driven by the globalisation of clinical trials for seasonal infectious diseases and vaccines. Global and local CROs will benefit from the increased demand for new vaccines and antiviral therapies in emerging markets, visiongain believes. However, growth in this sector will be restrained by the pharmaceutical industry’s reluctance to invest in new antibacterial drug development. Continued use of non-inferiority trials will also continue to be a challenge in this sector.

Metabolic Disease Clinical Trials: Key Trends and Submarket Forecast 2013-2023

As with many of the disease discussed in this chapter, incidence of most metabolic disorders is expected to rise rapidly in this decade. Drug developers are focused particularly on treating diabetes and obesity, two indications increasingly common in both developed and emerging markets. The World Health Organization (WHO) estimates that the number of people suffering from diabetes will rise from around 250 million in 2010 to approximately 380 million in 2030.